WO2012073881A1 - 大建中湯のバイオアッセイ方法およびこれを用いる品質管理方法 - Google Patents
大建中湯のバイオアッセイ方法およびこれを用いる品質管理方法 Download PDFInfo
- Publication number
- WO2012073881A1 WO2012073881A1 PCT/JP2011/077360 JP2011077360W WO2012073881A1 WO 2012073881 A1 WO2012073881 A1 WO 2012073881A1 JP 2011077360 W JP2011077360 W JP 2011077360W WO 2012073881 A1 WO2012073881 A1 WO 2012073881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- daikenchuto
- serotonin
- test
- preparation
- bioassay
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5064—Endothelial cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/507—Pancreatic cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Definitions
- the present invention relates to a bioassay method for Daikenchuto, and more specifically, using a cultured serotonin-producing cell, quantitatively evaluating the pharmacological activity value (serotonin releasing activity) of Daikenchuto, a Kampo preparation.
- the present invention relates to a bioassay method and a quality control method for Daikenchuto using the same.
- Chinese herbal medicine is a medicinal product blended with herbal medicines, and not all active ingredients are specified.
- a single active ingredient does not exert its effect, it acts in a complex manner with multiple ingredients, so in order to guarantee its quality, a measuring method that can be evaluated as a whole preparation Is said to be necessary.
- the US FDA herbal medicine guidance requires quality control by bioassay for products such as herbal medicine.
- This quality control method includes a method for measuring all components that are thought to be related to medicinal effects and comprehensively evaluating them, and a bioassay for evaluating biological activity using biological materials.
- Bioassays include in vivo tests and in vitro tests, but the in vivo test system has various limitations in terms of test facilities, test animals, and processing capacity. It was difficult to use for the quality evaluation of Chinese medicine.
- in-vitro test systems do not require special facilities and stable test results can be obtained in a short period of time, so it is required to establish a bioassay method in this system.
- an appropriate bioassay system has not always been found, and its establishment is awaited.
- an object of the present invention is to provide a bioassay method based on a simple test tube test for Daikenchuyu, and to provide a more accurate quality control method for Daikenchuyu using this method.
- Non-patent Document 1 Non-patent Document 1
- Daikenchuto and serotonin We conducted earnest research on the relationship.
- Daikenchuto has a serotonin release promoting action on serotonin-producing cells, and by measuring the amount of released serotonin, the pharmacological activity value of Daikenchuto can be measured. It was found that this was possible, and that the quality control of Daikenchuto could be appropriately performed by using this bioassay system, and the present invention was completed.
- the present invention adds a test sample containing Daikenchuto to cultured serotonin-producing cells, and then measures the serotonin content in the culture supernatant. Is the method.
- the present invention evaluates the pharmacological activity under the same conditions of the reference preparation and the test preparation, which have clinically recognized pharmacological effects as Daikenchuto, by the bioassay method of pharmacological activity of Daikenchuto described above,
- This is a quality control method for Daikenchuto preparations, characterized by evaluating the equivalence between a reference preparation and a test preparation.
- the bioassay method of the present invention it is possible to measure the pharmacological activity value (serotonin releasing activity) of Daikenchuto by a simple in vitro test without any restrictions on test facilities, test animals, processing ability, etc.
- this test by performing this test in an appropriate concentration range for evaluating quality, quality control with high accuracy can be performed for Daikenchuto.
- Daikenchuto is generally a powdered extract of mixed herbal medicines having the composition shown in Table 1 (sometimes referred to as Kowi Daikenchuto). (Kouyi English name: maltose).
- Daikenchuto which becomes the object of the bioassay method of the present invention
- Daikenchuto formulation which is added to Daikenchuto and further added as a pharmaceutical additive and formulated into granules etc.
- Examples of such a formulated Daikenchuto preparation include those marketed as ethical drugs such as TSUMURA Daikenchuto extract granules (medical use).
- ingredients that are approved as additives for the above-mentioned pharmaceuticals include starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, inorganic salts and other excipients, disintegrants, surfactants, lubricants , Fluidity promoters, flavoring agents, colorants, fragrances and the like.
- a test sample containing Daikenchuto is added to cultured serotonin producing cells, and the pharmacological activity value of Daikenchuto from the amount of serotonin released in the serotonin producing cells after the addition. Is to evaluate.
- Examples of serotonin-producing cells used in the present invention include enterochromaffin cells.
- This enterochromaffin cell is an endocrine cell and can produce and secrete a large amount of serotonin present in the living body. From the fact that 90% of the serotonin present in the living body is present in the enterochromaffin cells of the intestine, enterochromaffin cells of the intestine can be preferably used.
- an enterochromaffin-like cell line capable of producing a certain stable serotonin can also be used.
- enterochromaffin-like cell lines include RIN-14B cells derived from rat pancreatic cancer, QGP-1 cells derived from human pancreatic cancer, and KRJ-I cells derived from human small intestine carcinoid.
- particularly preferred cell lines include RIN-14B cells because of their excellent proliferation ability.
- serotonin-producing cells are cultured in a medium suitable for their growth, for example, a medium such as RPMI 1640 containing antibiotics, serum, etc., for example, for 1 to 3 days.
- a medium suitable for their growth for example, a medium such as RPMI 1640 containing antibiotics, serum, etc., for example, for 1 to 3 days.
- a test sample containing Daikenchuto is generally dissolved or suspended in a solvent such as dimethyl sulfoxide (DMSO) and added to the medium.
- a solvent such as dimethyl sulfoxide (DMSO)
- a known method can be used without particular limitation as long as it can measure the amount of released serotonin.
- Preferred methods include enzyme immunoassay (EIA method) and HPLC. Can be mentioned.
- the EIA method used in the present invention is a method of measuring the binding amount of an antigen-antibody reaction by attaching an enzyme to an antigen or antibody that undergoes a specific antigen-antibody reaction and measuring the activity of the enzyme.
- a commercially available kit such as EIA serotonin kit (manufactured by Beckman Coulter) can be used.
- the amount of sample charge, the type of analytical column, the diameter and length of the analytical column, the temperature of the analytical column, the composition of the mobile phase can be appropriately selected, and the conditions most suitable for the separation of serotonin may be selected. Such conditions are preferably such that the serotonin retention time (retention time) does not overlap with other detected substances.
- the analytical column a commonly used column, for example, a column filled with ODS or the like, and a generally used electrochemical detector (ECD) or the like can be used as the detector.
- a statistically significant reaction is preferably obtained in a concentration range (0 to 900 ⁇ g / mL) in which a concentration-dependent reaction is obtained as seen in the results of Example 1.
- concentration range 90-900 ⁇ g / mL
- the bioassay method of the present invention When evaluating the quality of Daikenchuto, which is a product, using the bioassay method of the present invention, first, the pharmacological activity value (serotonin releasing activity) of multiple lots of Daikenchuto that clinically had a pharmacological effect. ) And set the standard range based on that value. Next, by the same method, the pharmacological activity value (serotonin releasing activity) of the sample for quality test of Daikenchuto to be evaluated is measured. Then, the equivalence is evaluated based on whether or not the pharmacological activity value of the sample is within the set standard range, and quality control may be performed by setting an acceptable product as an acceptable product.
- Example 1 Daikenchuto bioassay test (1) Preparation of test sample: The herbal medicine mixture having the blending ratio shown in Table 1 was extracted by heating at 100 ° C. for 1 hour with purified water in an amount 10 times the weight of the mixture, and powdered to obtain Kowi Daikenchuto extract powder. This Koui Daikenchuto extract powder was made into a 100 mg / mL concentration of DMSO suspension, and this was mixed at a ratio of 1: 9 with an 88.8 mg / mL concentration aqueous koji solution to obtain a 90 mg / mL concentration. A Daikenchuto solution was prepared. This was diluted with 0.1% BSA-Hanks buffer * to a concentration of 9 mg / mL, followed by sonication for 15 minutes to prepare a Daikenchuto test sample.
- allyl isothiocyanate (AITC, Wako Pure Chemical Industries) was added to DMSO to prepare a DMSO solution of 100 mmol / L AITC.
- BSA-Hanks buffer 1 g bovine serum albumin, 1 g glucose, 8 g sodium chloride, 400 mg potassium chloride, 47.9 mg sodium monohydrogen phosphate (anhydrous), 60 mg potassium dihydrogen phosphate in 1 liter of distilled water (Anhydrous), 46.8 mg magnesium chloride (anhydrous), 48.8 mg magnesium sulfate (anhydrous), 140 mg calcium chloride (anhydrous) were dissolved and adjusted to pH 7.2 to 7.4.
- Rat pancreatic cancer cell line RIN-14B (manufactured by DS Pharma Biomedical) was added to RPMI 1640 medium (10 mmol / L HEPES, 1.5 g / L NaHCO 3 , 100 U / mL penicillin G) supplemented with 10% fetal bovine serum (FBS). And 100 ⁇ g / mL streptomycin) to obtain serotonin-producing cells. The cells were collected using trypsin-EDTA solution.
- Serotonin (5-HT) release test The serotonin-producing cells obtained in (2) above were dispensed at 3 ⁇ 10 4 cells / 100 ⁇ L / well in a 96-well flat bottom plate. After 72 hours of pre-culture, the culture supernatant was replaced with 0.1% BSA-Hanks buffer containing each test sample obtained in (1) above, and further 1 hour in a 5% carbon dioxide incubator. Cultured.
- Test samples were serially diluted with 0.1% BSA-Hanks buffer containing 1% DMSO and added to the final concentrations of 27, 90, 270, and 900 ⁇ g / mL in the culture system. The final concentration of was 0.1%.
- the positive control sample obtained in (1) above was added so that the final concentration was 100 ⁇ mol / L and the final concentration of DMSO was 0.1% in the culture system.
- the culture supernatant was centrifuged at 320 g for 5 minutes at 4 ° C., and the supernatant was used as a 5-HT concentration measurement sample (hereinafter referred to as “measurement sample”).
- the measurement sample obtained in (3) above was added to the tube containing the acylating reagent, and 50 ⁇ L of the acylating buffer was further added, followed by vortexing until the reagent was dissolved.
- the reaction was carried out for 30 minutes at room temperature under light-shielded conditions to obtain an acylation reaction solution.
- a system to which no measurement sample was added was treated in the same manner as above and used as a control.
- each acylation reaction solution is transferred to an appropriate well of a 96-well plate coated with an anti-5-HT antibody, and 200 ⁇ L of acetylcholinesterase (ACE) -5-HT conjugate is added at room temperature under light-shielding conditions. Incubated competitively for 3 hours with shaking in a plate mixer.
- ACE acetylcholinesterase
- the plate was washed 3 times with 300 ⁇ L / well to remove unbound substances, and then 200 ⁇ L / well of ACE substrate was added and left for 15 to 20 minutes. After confirming color development, 50 ⁇ L of a reaction terminator was added to stop the reaction, and the absorbance at 405 nm was measured. The result is shown in FIG.
- the 5-HT analysis by HPLC was performed under the following conditions.
- the 5-HT standard solution was prepared with a 0.1 mol / L acetic acid aqueous solution to which EDTA was added so that the final concentration was 100 mg / L.
- HPLC analysis conditions Trace biological sample analysis system: HTEC-500 (EICOM) Data processor: EPC-300 (EICOM) Data analysis software: PowerChrom version 2.5.7 (eDAQ) Analytical column: EICOMMPAK CA-5ODS 2.1mm ⁇ ⁇ 150mm Precolumn: EICOM PREPAKSET-CA 3.0mm ⁇ ⁇ 4mm Mobile phase: 80% 0.1 M phosphate buffer (Na + ) pH 6 20% methanol 500mg / L 1-octane sulfonic acid soda (SDS) 50 mg / L EDTA ⁇ 2Na + Flow rate: 230 ⁇ L / min Analysis temperature: 25 ° C Setting applied voltage: +450 mV (+400 to +450 mV) vs. Ag / AgCl Working electrode: Graphite electrode WE-3G Gasket: GS-25 Analytical column: 80%
- Daikenchuyu when evaluating the quality of Daikenchuto, there are almost no restrictions on test facilities, test animals, processing capacity, etc., and the test is possible, and further, by performing the test in an appropriate concentration range. , Daikenchuyu can be evaluated with high accuracy.
- the present invention is highly advantageous in quality control of Kampo preparations because it is more economical than conventional Daikenchuto bioassay methods and can be easily evaluated for quality.
Abstract
Description
大建中湯のバイオアッセイ試験:
(1)被験試料の調製:
表1の配合割合の生薬混合物を、その混合物重量の10倍量の精製水で1時間、100℃で加熱抽出し、粉末化することにより無コウイ大建中湯エキス末を得た。この無コウイ大建中湯エキス末を100mg/mL濃度のDMSO懸濁液とし、これを、88.8mg/mL濃度の膠飴水溶液に対して1:9の割合で混和し、90mg/mL濃度の大建中湯溶液を調製した。これを0.1%BSA-Hanks緩衝液*で希釈して9mg/mL濃度としたのち15分間の超音波処理を行い、大建中湯被験試料を調製した。
1リットルの蒸留水に1gウシ血清アルブミン、1gブドウ糖、8g塩化ナトリウム、400mg塩化カリウム、47.9mgリン酸一水素ナトリウム(無水)、60mgリン酸二水素カリウム(無水)、46.8mg塩化マグネシウム(無水)、48.8mg硫酸マグネシウム(無水)、140mg塩化カルシウム(無水)を溶解し、pH7.2~7.4に調製した。
ラット膵臓癌細胞株RIN-14B(DSファーマバイオメディカル社製)を、10%牛胎児血清(FBS)を加えたRPMI1640培地(10mmol/L HEPES、1.5g/L NaHCO3、100U/mL ペニシリン Gおよび100μg/mL ストレプトマイシン)中で継代培養し、セロトニン産生細胞とした。なお、細胞の回収にあたっては、トリプシン-EDTA液を用いた。
上記(2)で得られたセロトニン産生細胞を、96穴平底プレートに3×104cells/100μL/wellで分注した。72時間の前培養を行なった後、培養上清を上記(1)で得た各被験試料を含む0.1%BSA-Hanks緩衝液に置換し、5%炭酸ガスインキュベーターの中で更に1時間培養した。
EIA法による5-HT放出測定は、EIA セロトニン・キット(ベックマン・コールター社製)を用い、製品の添付プロトコールに準じて行った。
次に、(3)で得られた測定用試料のうち、900μg/mL大健中湯のものと、コントロールのものの培養試料液について、HPLCを用い、これに含まれる5-HTを検出した。その結果を図2の(a)および(b)に示す(5-HTの保持時間は、(a)で16.27分、(b)で16.11分である)。
微量生体試料分析システム:HTEC-500(EICOM)
データ処理装置:EPC-300(EICOM)
データ解析ソフトウェア:PowerChrom version
2.5.7(eDAQ)
分析カラム:EICOMPAK CA-5ODS
2.1mmΦ×150mm
プレカラム:EICOM PREPAKSET-CA
3.0mmΦ×4mm
移動相:80% 0.1M リン酸緩衝液(Na+)pH6
20% メタノール
500mg/L 1-オクタンスルホン酸ソーダ(SDS)
50mg/L EDTA・2Na+
流速:230μL/min
分析温度:25℃
設定加電圧:+450mV(+400~+450mV) vs
Ag/AgCl
作用電極:グラファイト電極 WE-3G
ガスケット:GS-25
分析カラム:80%
Claims (5)
- 培養セロトニン産生細胞に、大建中湯を含有する被験試料を添加し、次いで培養上清中のセロトニン含量を測定することを特徴とする大建中湯の薬理活性のバイオアッセイ方法。
- セロトニン産生細胞が、エンテロクロマフィン様細胞である請求項第1項記載の大建中湯の薬理活性のバイオアッセイ方法。
- セロトニン産生細胞が、RIN-14B細胞、QGP-1細胞およびKRJ-I細胞から選ばれる細胞株である請求項第1項または第2項記載の大建中湯の薬理活性のバイオアッセイ方法。
- 請求項1ないし3の何れかの項記載の大建中湯の薬理活性のバイオアッセイ方法により、大建中湯として臨床的に薬理効果が認められた基準製剤と被検製剤を同一条件で薬理活性を評価し、基準製剤と被検製剤の同一性を評価することを特徴とする大建中湯製剤の品質管理方法。
- 大建中湯の濃度として、90~900μg/mLの範囲でバイオアッセイ方法を行う請求項4記載の大建中湯製剤の品質管理方法。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/991,174 US9121846B2 (en) | 2010-12-03 | 2011-11-28 | Daikenchuto bioassay method and quality management method using same |
EP11844371.2A EP2647722B1 (en) | 2010-12-03 | 2011-11-28 | Daikenchuto bioassay method and quality management method using same |
JP2012546855A JP5884736B2 (ja) | 2010-12-03 | 2011-11-28 | 大建中湯のバイオアッセイ方法およびこれを用いる品質管理方法 |
KR1020137013088A KR101652737B1 (ko) | 2010-12-03 | 2011-11-28 | 대건중탕의 생물학적 검정 방법 및 이것을 사용하는 품질관리 방법 |
CN201180057641.5A CN103237899B (zh) | 2010-12-03 | 2011-11-28 | 大建中汤的生物测定方法及使用该方法的质量管理方法 |
HK14100179.7A HK1187376A1 (zh) | 2010-12-03 | 2014-01-08 | 大建中湯的生物測定方法及使用該方法的質量管理方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-270643 | 2010-12-03 | ||
JP2010270643 | 2010-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012073881A1 true WO2012073881A1 (ja) | 2012-06-07 |
Family
ID=46171813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/077360 WO2012073881A1 (ja) | 2010-12-03 | 2011-11-28 | 大建中湯のバイオアッセイ方法およびこれを用いる品質管理方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9121846B2 (ja) |
EP (1) | EP2647722B1 (ja) |
JP (1) | JP5884736B2 (ja) |
KR (1) | KR101652737B1 (ja) |
CN (1) | CN103237899B (ja) |
HK (1) | HK1187376A1 (ja) |
TW (1) | TW201305349A (ja) |
WO (1) | WO2012073881A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017169783A1 (ja) * | 2016-03-29 | 2017-10-05 | 株式会社ツムラ | 大建中湯の効果予測方法および投与量決定方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105796483A (zh) * | 2014-12-29 | 2016-07-27 | 四川滇虹医药开发有限公司 | 一种中药口服液及其制备方法 |
CN117214340B (zh) * | 2023-09-26 | 2024-04-23 | 湖南易能生物医药有限公司 | 一种包含花椒的中药组合物的质量控制方法及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379714B1 (en) * | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
US6329197B2 (en) * | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
EP1025441A1 (en) * | 1997-10-23 | 2000-08-09 | Pharmaprint, Inc. | Pharmaceutical grade echinacea |
EP2072623A4 (en) * | 2006-10-06 | 2009-12-30 | Astellas Pharma Inc | SCREENING PROCESS FOR A PROKINETIC AGENT |
US20080293159A1 (en) * | 2007-05-24 | 2008-11-27 | Murray Goulburn Co-Operative Co. Ltd. | Validation Process |
-
2011
- 2011-11-28 EP EP11844371.2A patent/EP2647722B1/en active Active
- 2011-11-28 KR KR1020137013088A patent/KR101652737B1/ko active IP Right Grant
- 2011-11-28 WO PCT/JP2011/077360 patent/WO2012073881A1/ja active Application Filing
- 2011-11-28 US US13/991,174 patent/US9121846B2/en active Active
- 2011-11-28 JP JP2012546855A patent/JP5884736B2/ja active Active
- 2011-11-28 CN CN201180057641.5A patent/CN103237899B/zh active Active
- 2011-12-02 TW TW100144381A patent/TW201305349A/zh unknown
-
2014
- 2014-01-08 HK HK14100179.7A patent/HK1187376A1/zh unknown
Non-Patent Citations (8)
Title |
---|
HAYATO KAN; EIJI UCHIDA, THE MEDICAL ASSOCIATION OF NIPPON MEDICAL SCHOOL, vol. 6, no. 3, 2010, pages 127 - 129 |
KAN H. ET AL.: "Herbal Medicine Therapies for Digestive Disease: A Special Focus on Dai-kenchu-to", JOURNAL OF MEDICAL ASSOCIATION OF NIPPON MEDICAL SCHOOL, vol. 6, no. 3, June 2010 (2010-06-01), pages 127 - 129, XP055083665 * |
KONO T. ET AL.: "A Possible Mechanism by Which Daikenchuto (TU-100) Improves Intestinal Motility by Inducing Serotonin Release From Enterochromaffin Cells by the Transient Receptor Potential A1 Channel", GASTEROENTEROLOGY, vol. 140, no. 5 SUPPL.1, May 2011 (2011-05-01), pages S-523, XP055083669 * |
NAGANO T. ET AL.: "Effects ot Dai-kenchu-to on Levels of 5-Hydroxytryptamine (Serotonin) and Vasoactive Intestinal Peptides in Human Plasma.", BIOL. PHARM. BULL., vol. 23, no. 3, 2000, pages 352 - 353, XP055083663 * |
SATO Y. ET AL.: "Ettects ot pirenzepine on Dai-kenchu-to-induced elevation of the plasma neuropeptide levels in humans.", BIOL. PHARM. BULL., vol. 29, no. 1, 2006, pages 166 - 171, XP055083664 * |
See also references of EP2647722A4 * |
TOSHIAKI NAGANO ET AL.: "Shokakan Hormone ni Taisuru Daikenchuto no Eikyo", TDM KENKYU, vol. 17, no. 2, 2000, pages 151 - 152, XP008168398 * |
YOSHIO KASE ET AL.: "Kanpo Seizai no Bunkenteki na Kosatsu", NIIGATA MEDICAL JOURNAL, vol. 120, no. 10, 2006, pages 544 - 548, XP008168412 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017169783A1 (ja) * | 2016-03-29 | 2017-10-05 | 株式会社ツムラ | 大建中湯の効果予測方法および投与量決定方法 |
CN108779484A (zh) * | 2016-03-29 | 2018-11-09 | 株式会社津村 | 大建中汤的效果预测方法和给药量确定方法 |
US11203775B2 (en) | 2016-03-29 | 2021-12-21 | Tsumura & Co. | Method for predicting effect of Daikenchuto and method for determining dosage of Daikenchuto |
Also Published As
Publication number | Publication date |
---|---|
US9121846B2 (en) | 2015-09-01 |
TWI561633B (ja) | 2016-12-11 |
KR20140001911A (ko) | 2014-01-07 |
EP2647722A1 (en) | 2013-10-09 |
TW201305349A (zh) | 2013-02-01 |
US20130260401A1 (en) | 2013-10-03 |
EP2647722B1 (en) | 2016-07-06 |
JPWO2012073881A1 (ja) | 2014-05-19 |
KR101652737B1 (ko) | 2016-09-01 |
JP5884736B2 (ja) | 2016-03-15 |
EP2647722A4 (en) | 2015-01-07 |
CN103237899A (zh) | 2013-08-07 |
CN103237899B (zh) | 2016-08-10 |
HK1187376A1 (zh) | 2014-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chidley et al. | A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis | |
Von Essen et al. | Vitamin D controls T cell antigen receptor signaling and activation of human T cells | |
Yamaguchi et al. | Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys | |
Rajamäki et al. | Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome | |
Horning et al. | Use of saliva in therapeutic drug monitoring. | |
Zhang et al. | A tandem mass spectrometry assay for the simultaneous determination of acetaminophen, caffeine, phenytoin, ranitidine, and theophylline in small volume pediatric plasma specimens | |
Lash et al. | Comparison of three multiplex cytokine analysis systems: Luminex, SearchLight™ and FAST Quant® | |
Vukoti et al. | Stabilization of functional recombinant cannabinoid receptor CB2 in detergent micelles and lipid bilayers | |
Svensson et al. | Adiponectin, chemerin, cytokines, and dipeptidyl peptidase 4 are released from human adipose tissue in a depot-dependent manner: an in vitro system including human serum albumin | |
Pidkovka et al. | Epoxyeicosatrienoic acids (EETs) regulate epithelial sodium channel activity by extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated phosphorylation | |
Barnett et al. | Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (−)-epicatechin in healthy volunteers | |
JP5884736B2 (ja) | 大建中湯のバイオアッセイ方法およびこれを用いる品質管理方法 | |
Ferrannini et al. | Mannose is an insulin-regulated metabolite reflecting whole-body insulin sensitivity in man | |
Kothekar et al. | Quantitative Determination of Levofloxacin and Ambroxol hydrochloride in Pharmaceutical Dosage Form by Reversed-Phase High Performance Liquid Chromatography. | |
Montano et al. | Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss | |
Marioni‐Henry et al. | Sarcolemmal specific collagen VI deficient myopathy in a Labrador Retriever | |
JP7413624B2 (ja) | 血清ビタミンd代謝物の濃度の推定方法 | |
Long et al. | REX technologies for profiling and decoding the electrophile signaling axes mediated by Rosetta Stone proteins | |
Fox et al. | Frequent manipulation of resistance training variables promotes myofibrillar spacing changes in resistance-trained individuals | |
JP5434599B2 (ja) | 抑肝散のバイオアッセイ方法 | |
JP2005505306A (ja) | Torの活性を調節する化合物のスクリーニングおよび医薬的使用 | |
Chao et al. | Interleukin-4 restores insulin sensitivity in insulin-resistant osteoblasts by increasing the expression of insulin receptor substrate 1 | |
WO2011023102A1 (zh) | 通过检测肝脏x受体转录活性来确定中药制剂药效的方法 | |
CN109690316A (zh) | 测定细胞内配体靶蛋白相互作用持久力的方法 | |
Marinho et al. | STUDY OF THE SALIVA AND URINE METABOLOME IN KIDNEY TRANSPLANT RECIPIENTS AND ITS ASSOCIATION WITH PERIODONTAL DISEASE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11844371 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012546855 Country of ref document: JP |
|
REEP | Request for entry into the european phase |
Ref document number: 2011844371 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011844371 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20137013088 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13991174 Country of ref document: US |